Outset Medical Inc

Outset Medical Inc(OM)の株式分析

$4.100

-0.314 (-7.66%)終値時点

Loading chart…
高値
4.375
始値
4.210
出来高加重平均価格
4.12
出来高
163.02K
時価総額
214.13M
安値
3.890
売買代金
671.92K
EV/EBITDA(TTM)
-0.82

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.

outsetmedical.com

AI分析 of Outset Medical Inc (OM)

中立

Outset Medical Inc is currently not a strong buy due to its low current price of $4.02 and a high RSI of 43.084, indicating potential weakness in momentum. The forward P/E ratio is 0, suggesting uncertainty in earnings expectations. Additionally, the stock has lost 68.52% over the past year, which raises concerns about its long-term viability. However, the stock has shown some positive movement with a year-to-date change of +8.65%, indicating potential recovery. The main risk is the upcoming earnings report on November 4, 2026, where an EPS estimate of -0.84 could further impact investor sentiment negatively.

バリュエーション指標

Outset Medical Inc(OM)の現在の予想PERは0.00で、5年平均は-5.84です。

予想PER

割高
5年平均 P/E
-5.84
現在のP/E
0.00
割高
-1.00
割安
-10.68

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-4.71
現在のEV/EBITDA
-0.82
割高
-0.51
割安
-8.92

予想PSR

適正
5年平均 P/S
4.35
現在のP/S
0.60
割高
9.32
割安
-0.63

Alphio AI による OM の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%OM

$19.05

シナリオ価格

基

基本

基本 · 50%OM

$18.74

シナリオ価格

弱

弱気

弱気 · 25%OM

$14.07

シナリオ価格

OM を保有するクジラ

K

Konwave AG (Gold 2000)

+ を保有OM

+3.50%

3か月リターン

イベントタイムライン

2026-05-07 (ET)

16:50:00

Company Reports Q1 Revenue of $27.86M, Below Expectations

16:50:00

Outset Reiterates 2026 Revenue Guidance of $125M to $130M

2026-02-11 (ET)

16:10:00

Outset Medical Reports Q4 Revenue of $28.87M

16:10:00

Outset Provides 2026 Revenue Guidance of $125M to $130M

2026-01-27 (ET)

09:10:00

Outset Medical Receives FDA 510(k) Clearance

ニュース

OM のよくある質問 — Alphio AI が回答

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Outset Medical Inc is currently not a strong buy due to its low current price of $4.02 and a high RSI of 43.084, indicating potential weakness in momentum. The forward P/E ratio is 0, suggesting uncertainty in earnings expectations. Additionally, the stock has lost 68.52% over the past year, which raises concerns about its long-term viability. However, the stock has shown some positive movement with a year-to-date change of +8.65%, indicating potential recovery. The main risk is the upcoming earnings report on November 4, 2026, where an EPS estimate of -0.84 could further impact investor sentiment negatively.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める